Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).

被引：6

作者：

Hodi, F. Stephen

Postow, Michael Andrew

Chesney, Jason Alan

Pavlick, Anna C.

Robert, Caroline

Grossmann, Kenneth F.

McDermott, David F.

Linette, Gerald P.

Meyer, Nicolas

Giguere, Jeffrey K.

Agarwala, Sanjiv

Shaheen, Montaser F.

Ernstoff, Marc S.

Minor, David R.

Salama, April K.

Taylor, Matthew H.

Ott, Patrick Alexander

Jiang, Joel

Gagnier, Paul

Wolchok, Jedd D.

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Univ Louisville, Louisville, KY 40292 USA

[4] NYU, Perlmutter Canc Ctr, New York, NY USA

[5] Inst Gustave Roussy, Villejuif, France

[6] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[7] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[8] Washington Univ, St Louis, MO 63110 USA

[9] Inst Univ Canc, Toulouse, France

[10] Greenville Hlth Syst, Seneca, SC USA

[11] St Lukes Canc Ctr, Bethlehem, PA USA

[12] Temple Univ, Bethlehem, PA USA

[13] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA

[14] Cleveland Clin, Cleveland, OH 44106 USA

[15] Calif Pacific Ctr Melanoma Res, San Francisco, CA USA

[16] Duke Univ, Durham, NC USA

[17] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[18] Bristol Myers Squibb, Princeton, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.9518

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9518

引用

页数：2